This translates into more than a 1,300-fold reduction in CD33+CD34− FLT3D/Y AML cells in TCRFLT3D/Y-treated mice (Fig. 4d,e, Extended Data Fig. 9c and Supplementary Table 8). The gene discussed is CD34; the disease is acute myeloid leukemia.